Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis
2022 · JAMA Neurology · 78 citations
https://doi.org/10.1001/jamaneurol.2022.0901
R
Ryosuke Oki
Tonan Hospital(JP)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
63
Papers
424
Citations
10
h-index
11
i10-index
Ryosuke Oki is an academic researcher from Tonan Hospital. The author has contributed to research in topics: Amyotrophic Lateral Sclerosis Research & Renal cell carcinoma treatment & Neurogenetic and Muscular Disorders Research. The author has an h-index of 10, co-authored 54 publications.
ORCID: 0000-0002-8017-7863Papers by this author
worksSafety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial
2022 · EClinicalMedicine · 49 citations
https://doi.org/10.1016/j.eclinm.2022.101707
Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report
2017 · BMC Cancer · 24 citations
https://doi.org/10.1186/s12885-017-3785-4
301P Effectiveness and safety of adjuvant nivolumab after radical surgery for high-risk urothelial carcinoma: A preliminary report of real-world data from a single institution in Japan
2024 · Annals of Oncology · 1 citations
https://doi.org/10.1016/j.annonc.2024.10.320
An R83W mutation in Rab3A causes autosomal-dominant cerebellar ataxia
2026 · Human Molecular Genetics · 0 citations
https://doi.org/10.1093/hmg/ddaf186
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat